Current Role of Immunotherapy in Multiple Myeloma

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F98%3A00000038" target="_blank" >RIV/65269705:_____/98:00000038 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Current Role of Immunotherapy in Multiple Myeloma
Original language description
Myeloablative chemotherapy improved the results of multiple myeloma treatment but the disease remains incurable. Residual disease eradication is one of the main clues for further improvement of the prognosis of myeloma patients. New methods-consolidationtherapy, antibodies, gene therapy, interleukins, immunotoxines, dendritic cells, vaccines and induction of graft-versus-tumor effect, are tested in the phase I/II clinical trials. Adoptive cellular immunotherapy anf progress in inductions of graft versus myeloma effect are very promising. We are still not able to transfer very good preclinical result of immunotherapy into clinical result in vivo measured by event free and long-term survivals. Combination of myeloablative therapy followed a new type ofimmunotherapy focussing on residual disease eradication evaluated in the setting of sensitive disease may be optimal. Such approach could improve the current
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/IZ4253" target="_blank" >IZ4253: Interleukin-2 Activation of Autologous Peripheral blood stem cell.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
1998
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)